|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Altheos, Inc. Names Barbara Wirostko, M.D., Chief Medical Officer
9/30/2010 9:25:38 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Altheos, Inc., a biopharmaceutical company focused on next generation treatments for glaucoma and ocular hypertension, announced today that Barbara Wirostko, M.D., has been appointed Chief Medical Officer. Dr. Wirostko is a board certified ophthalmologist with glaucoma subspecialty training. Prior to joining Altheos, she was senior medical director and the glaucoma medical team lead at Pfizer where she was responsible for pipeline strategy in glaucoma, overseeing the pediatric development program and Global Medical Affairs Programs for the Xalabrands franchise. Prior to joining Pfizer, she was chief ophthalmologist specializing in glaucoma at the Huntington Medical Group PC in Huntington, NY. During her 10 years in practice, she was a clinical investigator for a number of pivotal glaucoma clinical trials.
|
|
|
|
|
|
|
|
|
|
|